The Efficacy and Safety of a Combined Alendronate and Calcitriol Agent (Maxmarvil): A Postmarketing Surveillance Study in Korean Postmenopausal Women with Osteoporosis

키워드

참고문헌 (28)

1. Kanis JA, "The diagnosis of osteoporosis", J Bone Miner Res, 9, pp.1137~1141 (1994)
2. Emaus N, "Bone mineral density at the hip in Norwegian women and men--prevalence of osteoporosis depends on chosen references: the Tromso Study", Eur J Epidemiol, 24, pp.321~328 (2009)
3. Tenenhouse A, "Estimation of the prevalence of low bone density in Canadian women and men using a populationspecific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos)", Osteoporos Int, 11, pp.897~904 (2000)
4. Shin CS, "Prevalence and risk factors of osteoporosis in Korea: A community-based cohort study with lumbar spine and hip bone mineral density", BONE, 47, pp.378~387, ELSEVIER SCIENCE INC
5. Cranney A, "Meta-analyses of therapies for postmenopausal osteoporosis: II. Meta-analysis of alendronate for the treatment of postmenopausal women", Endocr Rev, 23, pp.508~516 (2002)
6. Harris ST, "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group", JAMA, 282, pp.1344~1352 (1999)
7. Bone HG, "Ten years’ experience with alendronate for osteoporosis in postmenopausal women", N Engl J Med, 350, pp.1189~1199 (2004)
8. Kushida K, "Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study", J Bone Miner Metab, 22, pp.462~468 (2004)
9. Iwamoto J, "Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis", J Bone Miner Metab, 23, pp.238~242 (2005)
10. Holick MF, "Vitamin D deficiency", N Engl J Med, 357, pp.266~281 (2007)
11. Park HM, "The vitamin D nutritional Status of postmenopausal women in Korea", Korean J Bone Metab, 10, pp.47~55 (2003)
12. Ushiroyama T, "Effects of the combined use of calcitonin and 1 alphahydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin", Maturitas, 40, pp.229~238 (2001)
13. Frediani B, "Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: two years of continuous treatment", Clin Drug Investig, 15, pp.235~244 (1998)
14. Lee JY, "Development and validation of a short food frequency questionnaire for estimating calcium intake", Korean J Health Promot Dis Prev, 1, pp.8~17 (2001)
15. Lenchik L, "International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee. What is the role of serial bone mineral density measurements in patient management?", J Clin Densitom, 5, pp.S29~S38 (2002)
16. Rhee Y, "Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebocontrolled study", Osteoporos Int, 17, pp.1801~1807 (2006)
17. Shiraki M, "A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group", Osteoporos Int, 10, pp.183~192 (1999)
18. 소재성, "한국 폐경 여성에서 부갑상선 호르몬, 비타민 D와골대사 사이의 관계", Obstetrics & Gynecology Science, 47(1), pp.153~160 (2004), 대한산부인과학회
19. Schacht E, "Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs", J Musculoskelet Neuronal Interact, 7, pp.174~184 (2007)
20. Hung YJ, "Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus", Clin Drug Investig, 26, pp.559~565 (2006)
21. Briesacher BA, "Consequences of poor compliance with bisphosphonates", Bone, 41, pp.882~887 (2007)
22. Weycker D, "Compliance with osteoporosis drug therapy and risk of fracture", Osteoporos Int, 18, pp.271~277 (2007)
23. Ho AY, "Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women", Ann Pharmacother, 39, pp.1428~1433 (2005)
24. Adachi JD, "Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, doubleblind, placebo-controlled, exploratory study", Clin Ther, 31, pp.1747~1753 (2009)
25. Liberman UA, "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group", N Engl J Med, 333, pp.1437~1443 (1995)
26. Pols HA, "Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group", Osteoporos Int, 9, pp.461~468 (1999)
27. Wasnich RD, "Antifracture efficacy of antiresorptive agents are related to changes in bone density", J Clin Endocrinol Metab, 85, pp.231~236 (2000)
28. Watts NB, "Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk", J Clin Densitom, 7, pp.255~261 (2004)

관련 논문AI추천